Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer

Date

11 Sep 2017

Session

Gastrointestinal tumours, non-colorectal

Presenters

Angela Alistar

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

A.T. Alistar1, B. Pasche2, R. D'Agostino3, T. Pardee4, S. Luther5, R. Desnoyer6

Author affiliations

  • 1 Hematology Oncology, Atlantic Health System, 07962 - morristown/US
  • 2 Hematology Oncology, Wake forest university, winston salem/US
  • 3 Director Of Biostatistic Core, wake forest university, winston salem/US
  • 4 Cmo, Rafael Pharmaceuticals, Cranbury/US
  • 5 Clinical Operations, Rafael pharmaceuticals, Cranbury/US
  • 6 Hematology Oncology, Wake forest university, Winston Salem/US
More

Resources

Abstract 5988

Background

Stage IV pancreatic cancer is a lethal disease. Current standard practice is combination chemotherapy such as FOLFIRINOX or Gemcitabine and Abraxane. The glycolic and mitochondrial metabolism are aberrant in pancreatic cancer and translate into chemoresistance. Inhibition of glutamine metabolism can potentially synergize with therapies that increase intracellular reactive oxygen species such as FOLFIRINOX components. CPI- 613 is a novel antimitocondrial developed by Rafael Pharmaceuticals that showed preclinical activity in pancreatic cancer.

Methods

We designed a phase 1 study to evaluate for synergy between CPI -613 and FOLFIRINOX for patients with stage IV pancreatic cancer. Aims: To determine the maximum tolerated dose (MTD) of CPI- 613 when used in combination with modified FOLFIRINOX. To assess the safety of CPI-613 + modified FOLFIRINOX To obtain preliminary data on efficacy of treatment.

Results

Updated Results as of July, 2017 Toxicity: No deaths due to adverse events were reported. The MTD was identified at 500 mg/m2 and a total of 18 patients were treated at the MTD. The most common grade 3–4 non-hematological adverse events: hyperglycemia, hypokalemia, peripheral sensory neuropathy, diarrhea, and abdominal pain. The most common grade 3–4 hematological adverse events: neutropenia, lymphopenia, anemia and thrombocytopenia Preliminary efficacy: Of the 18 patients treated at MTD– 8 patients are alive and 3 patients are still on treatment. The median PFS is 10.4 months, 95% CI (119 to 560 days) – 3 patients are still alive and on treatment who have not progressed. Median overall survival is 20.1 months, data still maturing. The 95% CI cannot be accurately estimated yet. Three patients achieved a complete response.

Conclusions

CPI-613 is a first in class non-redox active lipoate derivative being tested in phase I clinical trial in combination with FOLFIRINOX. The MTD for CPI-613 was identified at 500mg/m2. The treatment combination is feasible and well-tolerated. The response rate was 61%, which is higher than FOLFIRINOX alone (31.6%). The median PFS is 10.4months and the median OS is 20.1 months, data still maturing. A randomized, international phase 3 study of FOLFIRINOX vs. m FOLFIRINOX+ CPI613 will open in 2018.

Clinical trial identification

NCT01835041, First received: April 16, 2013 Last updated: May 30, 2017 Last verified: May 2017

Legal entity responsible for the study

Wake Forest University, School of Medicine

Funding

Cornerstone Pharmaceutical now Rafael Pharmaceuticals

Disclosure

T. Pardee: Chief Medical Officer and employee of Rafael Pharmaceutical (name change on June 5th 2017 from Cornerstone Pharmaceutical). Dr Pardee has no stock or equity in the company. S. Luther: Employee of Rafael Pharmaceuticals and the COO of the company. He owns stock in the company. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings